Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
South Korea’s leading biologics companies will invest hundreds of billions of won to building additional plants that would push the total amount of private investments for the biohealth industry to 10 trillion won by 2023.
Samsung Biologics will pour 1.7 trillion won into its new Plant 4 while Celltrion will invest 500 billion won to its Global Life Science Research Lab and Plant 3, all in Songdo, Incheon.
As its action plan for a more robust bio-industry ecosystem, the Government also pledged a 1.7 trillion won budget in 2021, up 30 percent from last year’s. The budget will prioritize pharmaceuticals, medical devices, and digital health care.
Biohealth players are building an ecosystem for biologics in Songdo, which now hosts 60 South Korean and international bio-related companies, employing around 7,000.
About 10 trillion won of investment is expected to be made in the city by some 40 health care and venture capital firms by 2023.
It would boost manufacturing capacity by 20 percent and employ an additional 9,300.
The government envisions the biologics workforce to grow to 47,000 by 2025 in a joint effort with the academe.
The regional bio clusters of Songdo, Wonju in Gangwon Province, Osong in North Chungcheong Province, and Daegu will increase collaboration.
The biologics industry is globally increasing 4 percent annually, higher than shipbuilders at 2.9 percent and car manufacturers at 1.5 percent.
